| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2003;125:325-329
© 2003 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease (ACD) |
From the Department of Surgerya and the Laboratory of Hematology,b Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
Received for publication Jan 18, 2002. Revisions requested April 10, 2002; revisions received April 26, 2002. Accepted for publication June 2002. Address for reprints: Michel Carrier, MD, Research Center, Montreal Heart Institute, 5000 Bélanger St East, Montreal, Quebec, Canada H1T (E-mail: carrier{at}icm.umontreal.ca).
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1 There are very few contraindications to the use of standard heparin, but heparin-induced thrombocytopenia (HIT) is emerging as a significant complication. 2 Although the incidence of this immune-mediated reaction to heparin appears low (between 1% and 2%), the risk of thrombotic complications is well documented. 3,4 Because most patients with unstable angina are administered intravenous heparin for the medical management of the condition, heparin-associated thrombocytopenia is frequently recognized before coronary bypass grafting surgery. Thus, several investigators have attempted to find alternatives to heparin in patients undergoing CPB. 5,6
Danaparoid, a heparin-free mixture of glycosaminoglycans derived from the porcine intestinal mucosa, was suggested as an alternative to heparin in patients with HIT who underwent CPB. 2 Danaparoid offers several advantages, such as a more specific inhibition at the Xa level compared with that produced with heparin and a lower cross-reactivity with the heparin-induced antibodies compared with that seen with low-molecular-weight heparins. Also, danaparoid has several disadvantages, such as the lack of a direct neutralizing agent and a long half-life of 25 hours. 7 Moreover, the use of danaparoid and of all alternative agents to heparin during CPB has been associated with serious postoperative bleeding complications. 1,2
Although off-pump coronary artery bypass grafting (OPCABG) is widely performed in several institutions, the exact role and indications for the procedure remain undefined. 8 Several authors have suggested that OPCABG could especially benefit patients at high risk of complications related to the use of the CPB system. 9 OPCABG in patients with HIT could be an alternative to conventional coronary artery bypass grafting (CABG) with CPB if a valuable alternative to heparin could be used. Thus, we suggest that a low-dose administration of danaparoid in OPCABG is a valuable alternative to the use of heparin.
We therefore undertook a double-blind, prospective, randomized clinical trial to compare the anticoagulants danaparoid and heparin in patients undergoing OPCABG surgery. The primary objective of the study was to compare blood loss in patients undergoing OPCABG with standard heparin versus danaparoid. The secondary aim of the study was to determine the effect of the 2 drugs on the percentage of patients requiring any type of homologous blood product transfusions and the number of blood product units transfused per patient after surgical intervention. Finally, we looked to compare the safety of the 2 drugs by measuring antithrombotic effects and overall myocardial ischemic damage.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Operative procedure
Perioperative management was standardized in the 2 groups. OPCABG was performed with the use of commercially available myocardial stabilizers and previously reported surgical techniques. 10,11 In the control group heparin was administered as a 1 mg/kg bolus and was reversed with a 1 mg/kg dose of protamine sulfate after CABG. In the treated group danaparoid was administered as a 40 U/kg bolus, and a placebo was injected after CABG. Heparin, danaparoid, protamine, and the placebo injections were prepared by the hospital pharmacists and were administered blind to all physicians.
In both groups mediastinal drainage was achieved with a commercially available autotransfusion system.
Postoperative transfusion
Postoperative homologous blood products were administered according to the following criteria during the study period. The threshold for homologous red blood cell transfusion was 80 g/L. Clotting factors were administered for persistent bleeding only after discussion with our hematology consultant, who had access to the code of randomization if needed. Four units of fresh frozen plasma were given for persistent moderate (100-300 mL/h) or severe (300 mL/h for 2 hours) bleeding with an international normalized ratio of greater than 1.8. For bleeding patients with platelet counts of less than 80 x 109/L, 8 units of platelets were transfused, and 8 units of cryoprecipitate were administered for fibrinogen levels of less than 1.0 g/L.
Safety measurement of anticoagulant activity and myocardial damage
Serum cardiac troponin T levels were measured 24 and 48 hours after CABG to determine the overall ischemic damage in both groups. 12 Anti-Xa activity was also measured in the 2 groups of patients 30 minutes and 12 hours after administration of the study drugs to determine antithrombotic activity. The laboratory was unblinded to permit dosage of anti-Xa level appropriate with the anticoagulant used. Because danaparoid and unfractionated heparin have their own specific anti-Xa activity, heparin and danaparoid were used independently for calibration of standard curves. The biologic activity of both anticoagulants resides in their ability to accelerate the inhibitory effect of antithrombin on coagulation proteases. We used the IL test heparin kit (Instrumentation Laboratory, Lexington, Mass), which is based on a synthetic chromogenic substrate and on factor Xa inactivation. Anti-Xa level in patients is measured on ACL 3000 (Beckman Coulter, Inc) in 2 stages. First, to obtain a constant concentration of antithrombin III, purified antithrombin III is added to the tested plasma. Factor Xa is then added to the tested plasma in excess and is neutralized by heparin-antithrombin III of danaparoid-antithrombin III. Second, residual factor Xa is then quantified with a synthetic chromogenic substrate and is inversely proportional to the anti-Xa activity in the sample.
Statistical analysis
The study was designed to demonstrate equivalence in the postoperative blood loss values on the basis of our earlier experience with OPCABG. 10,13 It was estimated that 120 patients had to be randomized into 2 groups. Patients were randomized to the heparin group or the danaparoid group by use of a table of random digits by blocks of 4. The study was stopped for a preliminary analysis of the primary and secondary end points after enrolling 71 patients because it appeared clinically that some patients were administered a greater number of homologous blood transfusions compared with data from our earlier experience with patients undergoing OPCABG. 10,13
Blood tests and different measurements of standardized data were done according to a strict protocol identical in both groups. All data were prospectively collected from the chart of every enrolled patient by 3 research assistants. For the purpose of the study, the term transfusion refers to any administration of homologous blood products, including homologous packed red blood cell units, platelets, fresh frozen plasma, and cryoprecipitate units.
Data are expressed as means, SDs, and 95% confidence limits (CLs) when specified. Statistical comparisons were done with the unpaired Student t test, the 
2 test, and the Fischer exact test. Relative risk and the 95% CL was calculated to study the exposure of patients of the 2 groups to homologous blood transfusions. Univariate and multiple logistic regression analyses were performed to identify the relationship between the need for homologous blood transfusion and several clinical variables in the 2 groups. Data analysis was performed with the Number Cruncher Statistical System 2001 (NCSS Statistical Software).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
).
|
|
).
|
|
Univariate analyses performed to study risk factors related with blood transfusions in OPCABG showed that women with lower hemoglobin levels before CABG and the use of danaparoid were associated with higher transfusion requirements after the operation (Table 5). In a multivariable analysis the use of danaparoid remained the only risk factor significantly related to the need for blood transfusion after OPCABG (Table 6).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although mediastinal blood loss and the need for transfusions were higher in patients with danaparoid compared with in those with heparin (53% vs 27%, respectively), we have showed, in a recent study on reinfusion of mediastinal blood after on-pump cardiac surgery, that 55% of the reinfused patients were administered homologous blood products after the operation. 14 Thus, our group of off-pump patients receiving a low dose of the anticoagulant danaparoid showed similar blood losses and received a similar number of homologous blood products after the operation when compared with a group of on-pump patients receiving heparin. 14
Several authors have suggested that OPCABG with the use of heparin results in a decrease in the use of homologous blood products when compared with that seen in patients undergoing operations with the CPB system. 8,9 Results of the present study corroborate these reports. Only 27% of patients who underwent OPCABG with heparin required homologous blood products after the operation, the lowest rate that our group has reported in recent years. 14
Increased activated clotting time and anti-Xa activity values during surgical intervention in the 2 groups suggest that the antithrombotic effect of the 2 drugs was adequate during the operation. The higher blood losses and transfusion requirements in patients receiving danaparoid appear related to the prolonged and nonreversible effect of the drug. However, serum troponin T levels were similar in the 2 groups after CABG, suggesting that the overall ischemic damage was identical in the 2 groups.
Although the present results show a significant increase in the requirement of blood transfusions in patients who undergo OPCABG with danaparoid, we suggest that this approach is a valuable alternative to unfractionated heparin and CPB in patients with serious contraindications to the use of heparin. Bauer and colleagues 15 reported that one fifth of patients undergoing CPB surgery have heparin-induced platelet antibodies detectable before the procedure as result of prior exposure to heparin, and several more had antibodies after the operation. Heparin is far more immunogenic than has been appreciated. 16 Walls and coworkers 17 and Singer and associates 18 reported that unrecognized HIT in patients undergoing CPB results in serious bleeding and thromboembolic complications after the operation.
Other anticoagulants have been used as alternatives to heparin in patients undergoing CPB, but danaparoid is the drug most often used in clinical practice. 1,2 Because high doses of danaparoid in patients with CPB appears to result in bleeding complications after the operation, we chose a lower dose of danaparoid and an off-pump approach for CABG. 1 The peak anti-Xa activities measured in our patients with danaparoid are similar to levels reported by Frederiksen 1 in reviewing the surgical literature of patients undergoing operations with danaparoid. Yet mediastinal drainage and transfusion requirements remained higher with the use of danaparoid compared with heparin because of the long half-life and the absence of a specific antidote to the former drug.
Follis and Schmidt 2 suggested that the simplest strategy in patients with heparin-induced antibodies is to postpone the operation for 6 to 8 weeks and monitor the level of antibodies. Some reports suggest that it is safe to proceed with heparin if there are no antibodies. We suggest that OPCABG with danaparoid is a valuable alternative in patients in whom the wait appears to increase the surgical risk.
In conclusion, patients who underwent OPCABG with low-dose danaparoid were at greater risk of exposure to homologous blood products and required a greater number of transfusions compared with patients who underwent off-pump surgery with heparin. Antithrombotic activity was identical, and ischemic damage after CABG was also similar between drugs. Although a larger percentage of patients receiving danaparoid required blood transfusions, the percentage of patients being transfused with danaparoid OPCABG is similar to numbers seen in previous reports with CPB and heparin. Thus, OPCABG with danaparoid is a safe alternative in patients with HIT requiring CABG.
The present study suggest that OPCABG offers new approaches and valuable alternatives to patients who present preoperative risk factors associated with high morbidity when the operation is performed by using a more conventional approach with CPB. We suggest that HIT in patients who need immediate CABG is an indication for the use of OPCABG techniques and the anticoagulant danaparoid.
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Chaubey, S. J. Davidson, and A. C. DeSouza Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery Interactive CardioVascular and Thoracic Surgery, December 1, 2009; 9(6): 1023 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Gurbuz, W. G. Elliott, and A. A. Zia Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Cannon, J. Butterworth, R. D. Riley, and J. M. Hyland Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery Ann. Thorac. Surg., February 1, 2004; 77(2): 711 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koster and T. Fischer Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416. [Abstract] [PDF]
|
|
|
|
 |
|
 F. A. Baciewicz Jr Bivalirudin as alternative to both danaparoid and heparin in off-pump coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 2108 - 2109. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
